Patents by Inventor Berta Ponsati Obiols
Berta Ponsati Obiols has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11571407Abstract: The invention provides a therapy for lysosomal storage diseases and glycogenosis by treatment with compounds that promote exocytosis, preferably lysosomal exocytosis. The treatment of cells from patients affected by different lysosomal storage disorders with exocytosis activating compounds leads to a decrease in the accumulation of toxic substrate in the lysosomes, thus allowing the treatment, prevention and relief of the symptoms of many lysosomal storage disorders.Type: GrantFiled: December 19, 2014Date of Patent: February 7, 2023Assignee: BCN PEPTIDES, S.A.Inventors: Josep Farrera-Sinfreu, Leslie Matalonga Borrel, Laura Gort Mas, Roberto Pascual Martínez, Antonio Ferrer Montiel, Antonia Ribes Rubió, Berta Ponsati Obiols
-
Publication number: 20190184054Abstract: Compositions for the treatment of pain and/or inflammation comprising at least one peptide with the general formula (I) R1-AA-R2, its stereoisomers, mixtures thereof, and its cosmetically and pharmaceutically acceptable salts. Peptide with general formula (I), its stereoisomers, mixtures thereof, and its cosmetically and pharmaceutically acceptable salts for the treatment of pain and/or inflammation.Type: ApplicationFiled: December 27, 2018Publication date: June 20, 2019Applicant: BCN PEPTIDES, S.A.Inventors: Cristina Carreño Serraïma, Wim Van Den Nest, Antonio Ferrer Montiel, Maria Camprubí Robles, Jimena Fernández Carneado, Berta Ponsati Obiols
-
Publication number: 20160317489Abstract: SUMMARY The invention provides a therapy for lysosomal storage diseases and glycogenosis by treatment with compounds that promote exocytosis, preferably lysosomal exocytosis. The treatment of cells from patients affected by different lysosomal storage disorders with exocytosis activating compounds leads to a decrease in the accumulation of toxic substrate in the lysosomes, thus allowing the treatment, prevention and relief of the symptoms of many lysosomal storage disorders.Type: ApplicationFiled: December 19, 2014Publication date: November 3, 2016Applicant: BCN PEPTIDES, S.A.Inventors: Josep FARRERA-SINFREU, Leslie MATALONGA BORREL, Laura GORT MAS, Roberto PASCUAL MARTÍNEZ, Antonio FERRER MONTIEL, Antonia RIBES RUBIÓ, Berta PONSATI OBIOLS
-
Patent number: 9464129Abstract: The invention relates to peptides of general formula (I): R1-AA-R2??(I) which can regulate neuronal exocytosis, their stereoisomers and racemic or non-racemic mixtures thereof, and the cosmetically or pharmaceutically acceptable salts thereof, wherein AA is a sequence of 3 to 40 adjacent amino acids contained in the amino acid sequence of the SNAP-25 protein, R1 is selected from the group consisting of H or alkyl, aryl, aralkyl or acyl group; and R2 is selected from the group consisting of amino, hydroxyl or thiol, substituted or non-substituted with aliphatic or cyclic groups, with the condition that when R1 is H or acetyl, R2 is not non-substituted amino, hydroxyl or thiol. The invention also relates to a method of obtaining such peptides, cosmetic or pharmaceutical compositions containing them and their use to treat those conditions requiring neuronal exocytosis regulation, preferably for treating the skin.Type: GrantFiled: October 24, 2007Date of Patent: October 11, 2016Assignee: BCN PEPTIDES S.A.Inventors: Cristina Carreño Serraïma, Berta Ponsati Obiols, Wim Van Den Nest, Jimena Fernandez Carneado, Antonio Ferrer Montiel, Juan Cebrian Puche, Nuria Almiñana Domenech
-
Publication number: 20160185822Abstract: The invention relates to cortistatin analogues and their uses. The compounds of the invention are peptide ligands with potential application in the diagnosis, prevention or therapy of those pathologies where receptors capable of binding to cortistatin, specific or shared with other molecules such as somatostatin and/or ghrelin (GHSR), are expressed, being in addition more stable in serum than cortistatin.Type: ApplicationFiled: September 17, 2014Publication date: June 30, 2016Applicant: BCN PEPTIDES, S.A.Inventors: Berta PONSATI OBIOLS, Jimena FERNÁNDEZ CARNEADO, Josep FARRERA-SINFREU, Antonio PARENTE DUEÑA
-
Patent number: 9216208Abstract: A topical ophthalmic formulation of peptides and their use for the treatment and/or local prevention of ocular diseases, preferably posterior segment eye diseases.Type: GrantFiled: December 17, 2010Date of Patent: December 22, 2015Assignee: BCN Peptides, S.A.Inventors: Rafael Simó Canonge, Cristina Hernández Pascual, Jimena Fernández Carneado, Marc Gómez Caminals, Rlbera Jordana I Lluch, Josep Farrera Sinfreu, Berta Ponsati Obiols
-
Patent number: 8946154Abstract: Peptide derivatives, their stereoisomers, mixtures thereof and/or their pharmaceutically acceptable salts, a method of obtaining them, pharmaceutical compositions containing them and the use thereof for the treatment, prevention and/or diagnosis of those conditions, disorders and/or pathologies in which the sstr1, sstr2, sstr3, sstr4 and/or sstr5 somatostatin receptors are expressed.Type: GrantFiled: May 6, 2010Date of Patent: February 3, 2015Assignee: BCN Peptides, S.A.Inventors: Antonio Parente Dueña, Berta Ponsati Obiols, Jimena Fernández Carneado, Marc Gómez Caminals, Ribera Jordana I Lluch
-
Publication number: 20130210728Abstract: A topical ophthalmic formulation of peptides and their use for the treatment and/or local prevention of ocular diseases, preferably posterior segment eye diseases.Type: ApplicationFiled: December 17, 2010Publication date: August 15, 2013Applicant: BCN PEPTIDES, S.A.Inventors: Rafael Simó Canonge, Cristina Hernández Pascual, Jimena Fernández Carneado, Marc Gómez Caminals, RIbera Jordana I Lluch, Josep Farrera Sinfreu, Berta Ponsati Obiols
-
Publication number: 20120122781Abstract: Peptide derivatives, their stereoisomers, mixtures thereof and/or their pharmaceutically acceptable salts, a method of obtaining them, pharmaceutical compositions containing them and the use thereof for the treatment, prevention and/or diagnosis of those conditions, disorders and/or pathologies in which the sstr1, sstr2, sstr3, sstr4 and/or sstr5 somatostatin receptors are expressed.Type: ApplicationFiled: May 6, 2010Publication date: May 17, 2012Applicant: BCN PEPTIDES, S.A.Inventors: Antonio Parente Duena, Berta Ponsati Obiols, Jimena Fernandez Carneado, Marc Gomez Caminals, Ribera Jordana I Lluch
-
Publication number: 20110166071Abstract: The invention relates to a method for obtaining thymosins and/or the pharmaceutically acceptable salts thereof by means of solid-phase synthesis on polymeric supports, which comprises the steps of linearly synthesizing the thymus-derived peptides in solid phase, incorporating at least one Thr or Ser in the sequence, in pseudoproline dipeptide form, obtaining the thymosins by treating the peptidyl resin with trifluoroacetic acid, and purifying the thymosins by RP-HPLC. The present invention also protects the isolated and/or purified compound obtained by means of said method and also the use thereof in the preparation of a medicinal product.Type: ApplicationFiled: April 25, 2007Publication date: July 7, 2011Inventors: Jimena Fernandez Carneado, Berta Ponsati Obiols, Javier Clemente Rodriguez, Raimon Rubires Ferrer, Sergi Pavon Fernandez
-
Publication number: 20100021510Abstract: The invention relates to peptides of general formula (I): R1-AA-R2 ??(I) which can regulate neuronal exocytosis, their stereoisomers and racemic or non-racemic mixtures thereof, and the cosmetically or pharmaceutically acceptable salts thereof, wherein AA is a sequence of 3 to 40 adjacent amino acids contained in the amino acid sequence of the SNAP-25 protein, R1 is selected from the group consisting of H or alkyl, aryl, aralkyl or acyl group; and R2 is selected from the group consisting of amino, hydroxyl or thiol, substituted or non-substituted with aliphatic or cyclic groups, with the condition that when R1 is H or acetyl, R2 is not non-substituted amino, hydroxyl or thiol. The invention also relates to a method of obtaining such peptides, cosmetic or pharmaceutical compositions containing them and their use to treat those conditions requiring neuronal exocytosis regulation, preferably for treating the skin.Type: ApplicationFiled: October 24, 2007Publication date: January 28, 2010Inventors: Cristina Carreno Serraïma, Berta Ponsati Obiols, Wim Van Den Nest, Jimena Fernandez Carneado, Antonio Ferrer Montiel, Juan Cebrian Puche, Nuria Almiñana Domenech
-
Patent number: 6521599Abstract: A stable pharmaceutical formulation for intravenous or intramuscular administration of Octreotide, which is characterized in that the vehicle for injection of the peptide or pharmaceutically acceptable salts thereof contains glycine in concentrations ranging from 10 to 60 mM and aqueous solution of hydrochloric acid in sufficient quantity to adjust the pH of the formulation to values between 3.0 and 4.2.Type: GrantFiled: October 10, 2001Date of Patent: February 18, 2003Assignee: Lipotec, S.A.Inventors: Berta Ponsati Obiols, Gemma Jodas Farres, Francisco Javier Clemente Rodriguez, Sergi Pavon Fernandez, Jordi Bacardit Cabado
-
Publication number: 20020128204Abstract: A stable pharmaceutical formulation for intravenous or intramuscular administration of Octreotide, which is characterised in that the vehicle for injection of the peptide or pharmaceutically acceptable salts thereof contains glycine in concentrations ranging from 10 to 60 mM and aqueous solution of hydrochloric acid in sufficient quantity to adjust the pH of the formulation to values between 3.0 and 4.2.Type: ApplicationFiled: October 10, 2001Publication date: September 12, 2002Inventors: Berta Ponsati Obiols, Gemma Jodas Farres, Francisco Javier Clemente Rodriguez, Sergi Pavon Fernandez, Jordi Bacardit Cabado
-
Patent number: 6346601Abstract: A procedure for obtaining the somatostatin analog, octreotide by means of solid phase synthesis on polymer supports and by intervention of protector groups of the Fmoc/tBu type. It includes construction of the seven amino acid, Boc-D-Phe-Cys(Trt)-Phe-D-Trp-Lys(Boc)Thr(tBu)-Cys(Trt)-Cl-trityl-R linear peptide, in which R is a polymer; treatment of the resulting peptidyl-resin with acid, for detachment of the peptide from the resin; cycling the linear structure obtained by reaction with iodine before or after incorporation of the threoninol residue into the terminal carboxy end; incorporating the threoninol residue in solution upon the seven amino acid protected peptide with or without the disulfide bridge formed; and removing the protections at the N-terminus and at the side chains with a treatment with 70-95% TFA in presence of scavengers to obtain octreotide.Type: GrantFiled: January 29, 1999Date of Patent: February 12, 2002Assignee: Lipotec S.A.Inventors: Berta Ponsati Obiols, Gemma Jodas Farres, Marc Canas Poblet, Francisco Javier Clemente Rodriguez
-
Patent number: 5739272Abstract: A procedure for obtaining carbocalcitonin comprising the condensation of fragment 1, a docosapeptide corresponding to the carboxamide end of the carbocalcitonin sequence, conveniently protected and anchored on resin, with fragment 2 or 3, a nonapeptide corresponding to the amino end of the salmon calcitonin sequence, with a ready-formed cycle between the Asu and Ser residua, and the treatment of the complete peptide skeleton (fragment 6 or 7) with an acid to free the totally deprotected peptide from the resin.Type: GrantFiled: February 3, 1994Date of Patent: April 14, 1998Assignee: Lipotec, S.A.Inventors: Marcos Canas Poblet, Berta Ponsati Obiols, Gemma Jodas Farres, David Andreu Martinez